Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
chronic obstructive pulmonary disease (COPD)
Pharma
GSK sets $35 out-of-pocket price cap for its inhalers in the US
The drugmaker's commitment will start by January 1, 2025 and follows similar moves by peers Boehringer Ingelheim and AstraZeneca.
Zoey Becker
Mar 21, 2024 11:45am
AstraZeneca caps out-of-pocket inhaler costs at $35 in the US
Mar 18, 2024 11:02am
FDA speeds Sanofi, Regeneron's application for Dupixent in COPD
Feb 22, 2024 11:25pm
Theravance's COPD med Yupelri flunks head-to-head study
Jan 5, 2024 10:14am
GSK aims to slash carbon emissions with next-generation inhaler
Nov 21, 2023 10:16am
AstraZeneca hit with FDA warning letter over Breztri sales aid
Aug 16, 2023 5:28am